221 related articles for article (PubMed ID: 25856562)
1. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
[TBL] [Abstract][Full Text] [Related]
2. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
[TBL] [Abstract][Full Text] [Related]
3. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
[TBL] [Abstract][Full Text] [Related]
4. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
5. SPECT imaging of interleukin-6 receptor in ovarian tumor xenografts with a novel radiotracer of 99mTc-HYNIC-Aca-LSLITRL.
Li F; Zhang Z; Cheng T; Wei R; Dai Y; Lv M; Luo D; Zhu X; Ma D; Xi L; Dong Q; Ma X
Amino Acids; 2016 Jan; 48(1):91-101. PubMed ID: 26255282
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival.
Kleinegger F; Hofer E; Wodlej C; Golob-Schwarzl N; Birkl-Toeglhofer AM; Stallinger A; Petzold J; Orlova A; Krassnig S; Reihs R; Niedrist T; Mangge H; Park YN; Thalhammer M; Aigelsreiter A; Lax S; Garbers C; Fickert P; Rose-John S; Moriggl R; Rinner B; Haybaeck J
Biochim Biophys Acta Mol Basis Dis; 2019 Feb; 1865(2):308-321. PubMed ID: 30419338
[TBL] [Abstract][Full Text] [Related]
7. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma.
Ma H; Yan D; Wang Y; Shi W; Liu T; Zhao C; Huo S; Duan J; Tao J; Zhai M; Luo P; Guo J; Tian L; Mageta L; Jou D; Zhang C; Li C; Lin J; Lv J; Li S; Lin L
Cancer Sci; 2019 Mar; 110(3):950-961. PubMed ID: 30648776
[TBL] [Abstract][Full Text] [Related]
8. IL-6/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer.
Yousefi H; Momeny M; Ghaffari SH; Parsanejad N; Poursheikhani A; Javadikooshesh S; Zarrinrad G; Esmaeili F; Alishahi Z; Sabourinejad Z; Sankanian G; Shamsaiegahkani S; Bashash D; Shahsavani N; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A
Tumori; 2019 Feb; 105(1):84-91. PubMed ID: 30021477
[TBL] [Abstract][Full Text] [Related]
9. Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
Bixel K; Saini U; Kumar Bid H; Fowler J; Riley M; Wanner R; Deepa Priya Dorayappan K; Rajendran S; Konishi I; Matsumura N; Cohn DE; Selvendiran K
Int J Cancer; 2017 Nov; 141(9):1856-1866. PubMed ID: 28646535
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 receptor inhibitor suppresses bone metastases in a breast cancer cell line.
Wakabayashi H; Hamaguchi T; Nagao N; Kato S; Iino T; Nakamura T; Sudo A
Breast Cancer; 2018 Sep; 25(5):566-574. PubMed ID: 29557068
[TBL] [Abstract][Full Text] [Related]
11. The reduction of IL-6 gene expression, pAKT, pERK1/2, pSTAT3 signaling pathways and invasion activity by gallic acid in prostate cancer PC3 cells.
Heidarian E; Keloushadi M; Ghatreh-Samani K; Valipour P
Biomed Pharmacother; 2016 Dec; 84():264-269. PubMed ID: 27665471
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic blockade of the interleukin-6 receptor (IL-6R) allows sIL-6R generation by proteolytic cleavage.
Prenissl N; Lokau J; Rose-John S; Haybaeck J; Garbers C
Cytokine; 2019 Feb; 114():1-5. PubMed ID: 30557809
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-106a regulates phosphatase and tensin homologue expression and promotes the proliferation and invasion of ovarian cancer cells.
Chen L; Zhang F; Sheng XG; Zhang SQ; Chen YT; Liu BW
Oncol Rep; 2016 Oct; 36(4):2135-41. PubMed ID: 27510094
[TBL] [Abstract][Full Text] [Related]
14. TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling.
Epstein Shochet G; Brook E; Bardenstein-Wald B; Shitrit D
Respir Res; 2020 Feb; 21(1):56. PubMed ID: 32070329
[TBL] [Abstract][Full Text] [Related]
15. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6/interleukin-6 receptor complex promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells.
Xie Z; Tang S; Ye G; Wang P; Li J; Liu W; Li M; Wang S; Wu X; Cen S; Zheng G; Ma M; Wu Y; Shen H
Stem Cell Res Ther; 2018 Jan; 9(1):13. PubMed ID: 29357923
[TBL] [Abstract][Full Text] [Related]
17. TGF-β dampens IL-6 signaling in articular chondrocytes by decreasing IL-6 receptor expression.
Wiegertjes R; van Caam A; van Beuningen H; Koenders M; van Lent P; van der Kraan P; van de Loo F; Blaney Davidson E
Osteoarthritis Cartilage; 2019 Aug; 27(8):1197-1207. PubMed ID: 31054955
[TBL] [Abstract][Full Text] [Related]
18. Noncanonical IL6 Signaling-Mediated Activation of YAP Regulates Cell Migration and Invasion in Ovarian Clear Cell Cancer.
Azar WJ; Christie EL; Mitchell C; Liu DS; Au-Yeung G; Bowtell DDL
Cancer Res; 2020 Nov; 80(22):4960-4971. PubMed ID: 32917727
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma.
Mochizuki D; Adams A; Warner KA; Zhang Z; Pearson AT; Misawa K; McLean SA; Wolf GT; Nör JE
Oncotarget; 2015 Sep; 6(26):22822-35. PubMed ID: 26287605
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells.
Lokau J; Kleinegger F; Garbers Y; Waetzig GH; Grötzinger J; Rose-John S; Haybaeck J; Garbers C
PLoS One; 2020; 15(5):e0232612. PubMed ID: 32365119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
